Nghiên cứu gánh nặng bệnh tật toàn cầu năm 2017 cho thấy tăng huyết áp gây ra khoảng 925 nghìn ca tử vong, ảnh hưởng đến khoảng 1,4 tỷ người trên toàn thế giới. Tuân thủ làm tăng hiệu quả điều trị. Các nghiên cứu về tăng huyết áp trên thế giới và ở Việt Nam cho thấy tỷ lệ tuân thủ điều trị có sự biến động ở các vùng khác nhau, dao động từ 25 đến 45,2%. Mục tiêu nghiên cứu xác định tỷ lệ tuân thủ điều trị và một số yếu tố liên quan ở bệnh nhân tăng huyết áp ngoại trú tại bệnh viện Vũng Tàu năm 2023. Nghiên cứu cắt ngang được thực hiện trên 306 bệnh nhân tăng huyết áp từ tháng 1/2023 đến tháng 4/2023. Thang đo tuân thủ thuốc chung (GMAS) của Atta Abbas Naqvi được sử dụng. Nghiên cứu cho thấy 65,4% bệnh nhân tăng huyết áp tuân thủ GMAS 30-33 điểm (GMAS=33 chiếm 25,8%, GMAS=30-32 điểm chiếm 39,5%). Phân tích hồi quy logistic đa biến cho thấy kiểm soát tăng huyết áp (p < 0,01; OR = 3,005; 95% Cl = 1,701-5,311) và số lượng thuốc (p = 0,007; OR = 0,127; 95% Cl = 0,028-0,570) có ảnh hưởng đến việc tuân thủ điều trị có ý nghĩa thống kê.
在2017年的925个国家中，有1,4个国家的企业被评为 "优秀企业"。Tuân thủ làm tăng hiệu quả điều trị.在越南，您可以从您的网站上了解到，在您的网站上，您可以看到许多关于您的产品的信息，其中包括：您的产品名称、产品型号、产品规格、产品种类、产品价格、产品销售渠道、产品销售渠道、产品销售渠道、产品销售渠道、产品销售渠道、产品销售渠道、产品销售渠道、产品销售渠道、产品销售渠道、产品销售渠道、产品销售渠道、产品销售渠道、产品销售渠道、产品销售渠道、产品销售渠道、产品销售渠道、产品销售渠道、产品销售渠道、产品销售渠道、产品销售渠道、产品销售渠道、产品销售渠道、产品销售渠道、产品销售渠道、产品销售渠道、产品销售渠道、产品销售渠道、产品销售渠道、产品销售渠道、产品销售渠道、产品销售渠道、产品销售渠道、产品销售渠道、产品销售渠道。从2023年开始，该地区的经济将继续增长。现在的汉字包含306个汉语拼音，在2023年1月1日到2023年4月4日之间。阿塔-阿巴斯-纳克维（Atta Abbas Naqvi）是全球排雷行动处处长。有65.4%的人通过GMAS 30-33分的测试（GMAS=33分的人占25.8%，GMAS=30-32分的人占39.5%）。逻辑分析结果表明，GMAS=25.8%（GMAS=33；GMAS=30-32；GMAS=39.5%）和Sưng thuốc（P = 0.007；OR = 0,127; 95% Cl = 0,028-0,570) có ảnh hưởng đến việc tuân thủ tuị có ý nghĩa thống kê.
{"title":"Tình hình tuân thủ điều trị bệnh nhân ngoại trú tăng huyết áp tại bệnh viện Vũng Tàu năm 2023","authors":"Đinh Thị Thúy Hà, Trần Phúc","doi":"10.59882/1859-364x/213","DOIUrl":"https://doi.org/10.59882/1859-364x/213","url":null,"abstract":"Nghiên cứu gánh nặng bệnh tật toàn cầu năm 2017 cho thấy tăng huyết áp gây ra khoảng 925 nghìn ca tử vong, ảnh hưởng đến khoảng 1,4 tỷ người trên toàn thế giới. Tuân thủ làm tăng hiệu quả điều trị. Các nghiên cứu về tăng huyết áp trên thế giới và ở Việt Nam cho thấy tỷ lệ tuân thủ điều trị có sự biến động ở các vùng khác nhau, dao động từ 25 đến 45,2%. Mục tiêu nghiên cứu xác định tỷ lệ tuân thủ điều trị và một số yếu tố liên quan ở bệnh nhân tăng huyết áp ngoại trú tại bệnh viện Vũng Tàu năm 2023. Nghiên cứu cắt ngang được thực hiện trên 306 bệnh nhân tăng huyết áp từ tháng 1/2023 đến tháng 4/2023. Thang đo tuân thủ thuốc chung (GMAS) của Atta Abbas Naqvi được sử dụng. Nghiên cứu cho thấy 65,4% bệnh nhân tăng huyết áp tuân thủ GMAS 30-33 điểm (GMAS=33 chiếm 25,8%, GMAS=30-32 điểm chiếm 39,5%). Phân tích hồi quy logistic đa biến cho thấy kiểm soát tăng huyết áp (p < 0,01; OR = 3,005; 95% Cl = 1,701-5,311) và số lượng thuốc (p = 0,007; OR = 0,127; 95% Cl = 0,028-0,570) có ảnh hưởng đến việc tuân thủ điều trị có ý nghĩa thống kê.","PeriodicalId":508364,"journal":{"name":"Tạp chí Nghiên cứu Dược và Thông tin Thuốc","volume":" 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141677007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Van Thi-Hong Tran, Thi Van Anh Hoang, Viet Hung Lai, Thi Hong Khanh Do, Duc-Vinh Pham
Breast cancer is the most common malignancy and the second leading cause of death in women. While tamoxifen (TAM) remains to be a first-line agent for prevention and treatment of estrogen-receptor (ER) positive breast tumors, TAM resistance represents one of the biggest clinical challenges in breast cancer therapy. Therefore, there has been growing interest in the identification of novel agents including those of plant origin that enhance the TAM sensitivity of breast cancer cells. In the present study, we aimed to evaluate the synergistic effect of Erythrina variegata extract (EVE) and TAM on the suppression of breast cancer cell growth using MCF-7 cell model and conventional bioassays such as MTT and colony formation assay, cell cycle analysis, and immunocytochemistry. Interestingly, MTT assay in combination with Chou-Talalay analysis demonstrated the potent synergism between EVE and tamoxifen against MCF-7 cell survival. Additionally, co-treatment of MCF-7 cells with EVE and TAM more significantly suppressed colony formation, cell cycle progression, and the nuclear expression of proliferative marker Ki67 compared to TAM alone. These findings imply that EVE potentiates the anti-proliferative effect of TAM in MCF-7 breast cancer cells and may become a promising agent in the treatment of ER positive breast cancer.
乳腺癌是最常见的恶性肿瘤，也是导致女性死亡的第二大原因。尽管他莫昔芬（TAM）仍然是预防和治疗雌激素受体（ER）阳性乳腺肿瘤的一线药物，但他莫昔芬的耐药性是乳腺癌治疗中最大的临床挑战之一。因此，越来越多的人开始关注新型药物的鉴定，包括那些能增强乳腺癌细胞对 TAM 敏感性的植物源药物。在本研究中，我们使用 MCF-7 细胞模型和传统生物检测方法（如 MTT 和菌落形成检测、细胞周期分析和免疫细胞化学），旨在评估变节红景天提取物（EVE）和 TAM 对抑制乳腺癌细胞生长的协同作用。有趣的是，MTT 试验与 Chou-Talalay 分析相结合，证明了 EVE 和他莫昔芬对 MCF-7 细胞存活的强效协同作用。此外，与单独使用 TAM 相比，EVE 和 TAM 联合处理 MCF-7 细胞能更显著地抑制集落形成、细胞周期进展和增殖标志物 Ki67 的核表达。这些研究结果表明，EVE 能增强 TAM 在 MCF-7 乳腺癌细胞中的抗增殖作用，可能成为一种治疗 ER 阳性乳腺癌的有效药物。
{"title":"Synergistic effect of Erythrina variegata L. and tamoxifen against the growth of breast cancer cells","authors":"Van Thi-Hong Tran, Thi Van Anh Hoang, Viet Hung Lai, Thi Hong Khanh Do, Duc-Vinh Pham","doi":"10.59882/1859-364x/120","DOIUrl":"https://doi.org/10.59882/1859-364x/120","url":null,"abstract":"Breast cancer is the most common malignancy and the second leading cause of death in women. While tamoxifen (TAM) remains to be a first-line agent for prevention and treatment of estrogen-receptor (ER) positive breast tumors, TAM resistance represents one of the biggest clinical challenges in breast cancer therapy. Therefore, there has been growing interest in the identification of novel agents including those of plant origin that enhance the TAM sensitivity of breast cancer cells. In the present study, we aimed to evaluate the synergistic effect of Erythrina variegata extract (EVE) and TAM on the suppression of breast cancer cell growth using MCF-7 cell model and conventional bioassays such as MTT and colony formation assay, cell cycle analysis, and immunocytochemistry. Interestingly, MTT assay in combination with Chou-Talalay analysis demonstrated the potent synergism between EVE and tamoxifen against MCF-7 cell survival. Additionally, co-treatment of MCF-7 cells with EVE and TAM more significantly suppressed colony formation, cell cycle progression, and the nuclear expression of proliferative marker Ki67 compared to TAM alone. These findings imply that EVE potentiates the anti-proliferative effect of TAM in MCF-7 breast cancer cells and may become a promising agent in the treatment of ER positive breast cancer.","PeriodicalId":508364,"journal":{"name":"Tạp chí Nghiên cứu Dược và Thông tin Thuốc","volume":"284 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140447602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Nguyen Thu Hang, Than Thi Kieu My Than Thi Kieu, Nguyen Van Phuong
The objective of this study was to enhance the anti-hyperuricemic activity of modified Simiao wan (MSW) by optimizing the conditions of extraction of the active group of compounds determined from network pharmacology analysis. The main group of compounds involved in the uric acid lowering effect of MSW was identified based on the herb-compound-target network. After that, the optimal conditions of extraction of these compounds from MSW were determined using response surface methodology. Then, the biological effects of MSW extracted at optimal conditions and sub-optimal conditions were evaluated. The binding mode of the key compounds of MSW with the potent target was also explored using molecular docking and molecular dynamics. The results suggested that flavonoids, particularly quercetin, luteolin, kaempferol, and wogonin, might be important compounds involved in the anti-hyperuricemic activity of MSW. After that, the optimal conditions of extraction of flavonoid from MSW were determined, including ethanol concentration of 80% and time of extraction of 60 minutes. The results of the pharmacological assay indicated that MSW extracted at optimal conditions could significantly reduce uric acid levels compared with MSW extracted under sub-optimal conditions. The protein-protein interaction network, molecular docking, and molecular dynamics simulation showed that besides anti-hyperuricemic activity, flavonoids from MSW could also exhibit anti-inflammatory effects through inhibiting TNFα. Our study suggested that optimization of extraction based on network pharmacology analysis might be an effective approach to improve the therapeutic activity of this traditional medicine.
{"title":"Enhancement of The Anti-Hyperuricemic Activity of Modified Simiao Wan by Optimizing The Conditions of Extraction of The Active Compounds, Using Network Pharmacology Approach","authors":"Nguyen Thu Hang, Than Thi Kieu My Than Thi Kieu, Nguyen Van Phuong","doi":"10.59882/1859-364x/97","DOIUrl":"https://doi.org/10.59882/1859-364x/97","url":null,"abstract":"The objective of this study was to enhance the anti-hyperuricemic activity of modified Simiao wan (MSW) by optimizing the conditions of extraction of the active group of compounds determined from network pharmacology analysis. The main group of compounds involved in the uric acid lowering effect of MSW was identified based on the herb-compound-target network. After that, the optimal conditions of extraction of these compounds from MSW were determined using response surface methodology. Then, the biological effects of MSW extracted at optimal conditions and sub-optimal conditions were evaluated. The binding mode of the key compounds of MSW with the potent target was also explored using molecular docking and molecular dynamics. The results suggested that flavonoids, particularly quercetin, luteolin, kaempferol, and wogonin, might be important compounds involved in the anti-hyperuricemic activity of MSW. After that, the optimal conditions of extraction of flavonoid from MSW were determined, including ethanol concentration of 80% and time of extraction of 60 minutes. The results of the pharmacological assay indicated that MSW extracted at optimal conditions could significantly reduce uric acid levels compared with MSW extracted under sub-optimal conditions. The protein-protein interaction network, molecular docking, and molecular dynamics simulation showed that besides anti-hyperuricemic activity, flavonoids from MSW could also exhibit anti-inflammatory effects through inhibiting TNFα. Our study suggested that optimization of extraction based on network pharmacology analysis might be an effective approach to improve the therapeutic activity of this traditional medicine.","PeriodicalId":508364,"journal":{"name":"Tạp chí Nghiên cứu Dược và Thông tin Thuốc","volume":"219 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139145346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Phung Thanh Huong, Nguyen Thi Lap, Dao Thi Mai Anh, Nguyen Xuan Bac, Mai Van Hien, Pham Tran Thu Ha, Vu Thi Phuong
Colorectal cancer (CRC) ranks third in terms of incidence, but second in terms of mortality among all types of cancer globally. Despite emerging advances in cancer remedies, chemotherapy remains the major standard treatment for CRC patients. However, poor prognosis is still a great concern and chemoresistance is detected in 90% of patients with metastatic CRC. Recently, the reprogramming of multiple metabolisms in cancer cells has emerged as an essential effector in tumor growth and drivers of chemoresistance. Understanding the significant mechanisms of chemoresistance would help to find effective solutions to overcome drug resistance and improve the therapeutic efficacy of chemotherapy, thereby prolonging the survival of cancer patients. This review discusses the mechanisms of glucose metabolism reprogramming in the context of CRC chemoresistance and the perspectives of targeting glucose metabolism for the improvement of CRC therapy.
{"title":"The essential role of glucose metabolism in chemoresistance of colorectal cancer - a mini review","authors":"Phung Thanh Huong, Nguyen Thi Lap, Dao Thi Mai Anh, Nguyen Xuan Bac, Mai Van Hien, Pham Tran Thu Ha, Vu Thi Phuong","doi":"10.59882/1859-364x/155","DOIUrl":"https://doi.org/10.59882/1859-364x/155","url":null,"abstract":"Colorectal cancer (CRC) ranks third in terms of incidence, but second in terms of mortality among all types of cancer globally. Despite emerging advances in cancer remedies, chemotherapy remains the major standard treatment for CRC patients. However, poor prognosis is still a great concern and chemoresistance is detected in 90% of patients with metastatic CRC. Recently, the reprogramming of multiple metabolisms in cancer cells has emerged as an essential effector in tumor growth and drivers of chemoresistance. Understanding the significant mechanisms of chemoresistance would help to find effective solutions to overcome drug resistance and improve the therapeutic efficacy of chemotherapy, thereby prolonging the survival of cancer patients. This review discusses the mechanisms of glucose metabolism reprogramming in the context of CRC chemoresistance and the perspectives of targeting glucose metabolism for the improvement of CRC therapy.","PeriodicalId":508364,"journal":{"name":"Tạp chí Nghiên cứu Dược và Thông tin Thuốc","volume":"44 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139147196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
This study aimed to develop a stable lyophilized formulation and the tableting process of lyophilized powder to improve the stability of the enzyme alpha-chymotrypsin (ACT). The impacts of the bulking agent and stabilizer on the freeze-drying process and the stability of ACT were determined. The effects of the filler excipients and the compression force on the activity of ACT tablets containing lyophilized powder were also evaluated. The findings revealed that arginine HCl, which had a multipoint interaction with the surface of ACT, and the crystalline excipient mannitol stabilized the structure of the enzyme and the lyophilized cake. The dehydration process through freeze-drying effectively protected the active substance against denaturing factors such as heat, moisture, and mechanical force. The study also demonstrated that the use of elastic fillers such as compressuc and a minor compression force contributed to the enhancement of ACT tablet stability. In summary, the study successfully developed a formulation for tablets containing ACT lyophilized powder, initially overcoming the poor stability of this enzyme to environmental factors, showing the applicability of lyophilization and stabilizing excipients in enhancing the stability of biomolecules.
{"title":"Formulation of tablets containing lyophilized powder to improve the stability of alpha-chymotrypsin","authors":"Quoc Hoai Nguyen, The Khang Duong, Ngoc Quang Do, Vu Minh Duc, Thanh Tung Pham, Thi Lien Nguyen, Nguyen Thach Tung","doi":"10.59882/1859-364x/119","DOIUrl":"https://doi.org/10.59882/1859-364x/119","url":null,"abstract":"This study aimed to develop a stable lyophilized formulation and the tableting process of lyophilized powder to improve the stability of the enzyme alpha-chymotrypsin (ACT). The impacts of the bulking agent and stabilizer on the freeze-drying process and the stability of ACT were determined. The effects of the filler excipients and the compression force on the activity of ACT tablets containing lyophilized powder were also evaluated. The findings revealed that arginine HCl, which had a multipoint interaction with the surface of ACT, and the crystalline excipient mannitol stabilized the structure of the enzyme and the lyophilized cake. The dehydration process through freeze-drying effectively protected the active substance against denaturing factors such as heat, moisture, and mechanical force. The study also demonstrated that the use of elastic fillers such as compressuc and a minor compression force contributed to the enhancement of ACT tablet stability. In summary, the study successfully developed a formulation for tablets containing ACT lyophilized powder, initially overcoming the poor stability of this enzyme to environmental factors, showing the applicability of lyophilization and stabilizing excipients in enhancing the stability of biomolecules.","PeriodicalId":508364,"journal":{"name":"Tạp chí Nghiên cứu Dược và Thông tin Thuốc","volume":"10 24","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139147413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hoang Quynh Hoa, Pham Thi Linh Giang, Nguyen Thi Van Anh, Vu Thi Quyen, Nguyen Ngoc Hieu, Pham Ha Thanh Tung
Day khe (Cnestis palala (Lour.) Merr., Connaraceae) has been widely distributed in Hoa Binh province, Vietnam. The aqueous and ethanolic extracts of the stems of C. palala (10 mg/well) showed antibacterial effects on Staphylococcus aureus and Bacillus subtilis by agar diffusion method with diameter antibacterial zone values ranged from 8,3 ± 0,4 mm to 12,3 ± 0,4 mm. Maximum antibacterial activity was exhibited by ethanol 96 % extract against Staphylococcus aureus and Bacillus subtilis with MBC values of 5,2 and 41,5 mg/ml, respectively. This study aimed to isolate and evaluate the antimicrobial activity of some bioactive compounds from C. palala stem using bioguided fractionation. Their activities on S. aureus and S. epidermidis have been evaluated. Various chromatographical techniques were applied for isolation and purification. Antimicrobial activity was determined by multi-concentration dilution. Two bioactive compounds 3,4-dihydroxybenzoic acid (protocatechuic) (1) and 2,10-bis(3,4-dihydroxyphenyl)-3,5-dihydroxy-3,4,9,10-tetrahydro-2H,8H-pyrano[2,3-f]chromen-8-on (cinchonain) (2) were purified and determined structure. Their antimicrobial activities were confirmed using the microdilution method on S. aureus and S. epidermidis. The activity of compound 1 against S. aureus and S. epidermidis: MIC was 128 µg/ml and 16 µg/ml, respectively, and IC50 was 46,78 ± 1,36 µg/ml and 5,67 ± 1,36 µg/ml, respectively. The activity of compound 2 against S. aureus and S. epidermidis: MIC were 128 µg/ml và 16 µg/ml respectively, and IC50 was 43,23 ± 2,45 µg/ml and 6,34 ± 2,45 µg/ml, respectively. These results highlight the ethno-traditional use of Cnestis palala for infections and recommend further developing antimicrobial products.
{"title":"Bio-guided isolation of antimicrobial compounds from Cnestis palala","authors":"Hoang Quynh Hoa, Pham Thi Linh Giang, Nguyen Thi Van Anh, Vu Thi Quyen, Nguyen Ngoc Hieu, Pham Ha Thanh Tung","doi":"10.59882/1859-364x/15","DOIUrl":"https://doi.org/10.59882/1859-364x/15","url":null,"abstract":"Day khe (Cnestis palala (Lour.) Merr., Connaraceae) has been widely distributed in Hoa Binh province, Vietnam. The aqueous and ethanolic extracts of the stems of C. palala (10 mg/well) showed antibacterial effects on Staphylococcus aureus and Bacillus subtilis by agar diffusion method with diameter antibacterial zone values ranged from 8,3 ± 0,4 mm to 12,3 ± 0,4 mm. Maximum antibacterial activity was exhibited by ethanol 96 % extract against Staphylococcus aureus and Bacillus subtilis with MBC values of 5,2 and 41,5 mg/ml, respectively. This study aimed to isolate and evaluate the antimicrobial activity of some bioactive compounds from C. palala stem using bioguided fractionation. Their activities on S. aureus and S. epidermidis have been evaluated. Various chromatographical techniques were applied for isolation and purification. Antimicrobial activity was determined by multi-concentration dilution. Two bioactive compounds 3,4-dihydroxybenzoic acid (protocatechuic) (1) and 2,10-bis(3,4-dihydroxyphenyl)-3,5-dihydroxy-3,4,9,10-tetrahydro-2H,8H-pyrano[2,3-f]chromen-8-on (cinchonain) (2) were purified and determined structure. Their antimicrobial activities were confirmed using the microdilution method on S. aureus and S. epidermidis. The activity of compound 1 against S. aureus and S. epidermidis: MIC was 128 µg/ml and 16 µg/ml, respectively, and IC50 was 46,78 ± 1,36 µg/ml and 5,67 ± 1,36 µg/ml, respectively. The activity of compound 2 against S. aureus and S. epidermidis: MIC were 128 µg/ml và 16 µg/ml respectively, and IC50 was 43,23 ± 2,45 µg/ml and 6,34 ± 2,45 µg/ml, respectively. These results highlight the ethno-traditional use of Cnestis palala for infections and recommend further developing antimicrobial products.","PeriodicalId":508364,"journal":{"name":"Tạp chí Nghiên cứu Dược và Thông tin Thuốc","volume":" 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139144956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Phạm An Khánh, Đỗ Ngọc Quang, Nguyễn Thị Hoàn, Nguyễn Thạch Tùng
Nghiên cứu được thực hiện nhằm mục đích tìm ra công thức viên nén acid 5-aminosalicylic giải phóng kéo dài sử dụng hệ cốt trương nở hòa tan. Viên nén giải phóng kéo dài được bào chế bằng phương pháp tạo hạt ướt, sử dụng các tá dược hydroxypropyl methyl cellulose, Avicel PH101, Talc, magnesium stearate và tá dược dính. Tốc độ giải phóng của 5-ASA từ viên được đánh giá trên thiết bị thử hòa tan kiểu cánh khuấy trong môi trường đệm phosphat pH 7,5. Trên cơ sở nghiên cứu đánh giá tương tác dược chất - tá dược và các nghiên cứu đánh giá ảnh hưởng của yếu tố công thức và quy trình tới phần trăm giải phóng dược chất, nhóm nghiên cứu đã tìm ra được công thức viên nén 5-ASA dạng cốt giải phóng kéo dài. Đồ thị hòa tan của viên nghiên cứu ở môi trường pH 1,2 và 7,5 tương đồng với đồ thị hòa tan của viên đối chiếu Pentasa®
Nghiên cu được thc hiện nhằm mục đích tìm ra công thứn c viên nén acid 5-aminosalicylic giải phóng kéo dài sử dụng hốtệ c trương nở hòa tan.您可以使用羟丙基甲基纤维素、Avicel PH101、滑石粉、硬脂酸镁或其他材料。使用 5-ASA 来控制 PH 值为 7.5 的磷酸盐。如果您想了解更多信息，请联系我们、我们的 5-ASA 技术已被广泛应用。PH值为1.2或7.5时，可使用Pentasa®。
{"title":"Nghiên cứu bào chế viên nén acid 5-aminosalicylic dạng cốt giải phóng kéo dài","authors":"Phạm An Khánh, Đỗ Ngọc Quang, Nguyễn Thị Hoàn, Nguyễn Thạch Tùng","doi":"10.59882/1859-364x/154","DOIUrl":"https://doi.org/10.59882/1859-364x/154","url":null,"abstract":"Nghiên cứu được thực hiện nhằm mục đích tìm ra công thức viên nén acid 5-aminosalicylic giải phóng kéo dài sử dụng hệ cốt trương nở hòa tan. Viên nén giải phóng kéo dài được bào chế bằng phương pháp tạo hạt ướt, sử dụng các tá dược hydroxypropyl methyl cellulose, Avicel PH101, Talc, magnesium stearate và tá dược dính. Tốc độ giải phóng của 5-ASA từ viên được đánh giá trên thiết bị thử hòa tan kiểu cánh khuấy trong môi trường đệm phosphat pH 7,5. Trên cơ sở nghiên cứu đánh giá tương tác dược chất - tá dược và các nghiên cứu đánh giá ảnh hưởng của yếu tố công thức và quy trình tới phần trăm giải phóng dược chất, nhóm nghiên cứu đã tìm ra được công thức viên nén 5-ASA dạng cốt giải phóng kéo dài. Đồ thị hòa tan của viên nghiên cứu ở môi trường pH 1,2 và 7,5 tương đồng với đồ thị hòa tan của viên đối chiếu Pentasa®","PeriodicalId":508364,"journal":{"name":"Tạp chí Nghiên cứu Dược và Thông tin Thuốc","volume":"68 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139147118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Phạm Lê Minh, Ngô Minh Thúy, Đào Thị Hương, Vũ Thị Thu Trang, Nguyễn Thị Kiều Anh
Nghiên cứu đã xây dựng và thẩm định phương pháp sắc ký lớp mỏng hiệu năng cao (HPTLC) nhanh, đặc hiệu và chính xác để định lượng fenofibrat trong bán thành phẩm và viên nén. Pha tĩnh là bản mỏng nhôm tráng silicagel 60 F254, dung môi rửa giải gồm toluen - cloroform (4:7, tt/tt) cho vết chất phân tích gọn và rõ ràng (Rf là 0,50 ± 0,01). Chế độ đo độ hấp thụ ở bước sóng 298 nm bằng quét mật độ vết được sử dụng để định lượng. Phương pháp được thẩm định về độ chọn lọc, độ tuyến tính, độ đúng và độ chính xác theo hướng dẫn của ICH. Kết quả cho thấy, phương pháp có độ tuyến tính tốt (r = 0,999), độ chính xác trong ngày và độ chính xác khác ngày lần lượt là 0,73% và 0,98%, độ đúng nằm trong khoảng 98,1-100,3%. Phương pháp đã ứng dụng thành công trong định lượng chất phân tích trong cốm, bán thành phẩm và thành phẩm. Giá trị RSD của hàm lượng fenofibrate trong mẫu thử thấp (<1%) chứng tỏ phương pháp HPTLC xây dựng được phù hợp để áp dụng trong phân tích thường qui hoạt chất này trong kiểm tra chất lượng.
{"title":"Xây dựng và thẩm định phương pháp HPTLC để định lượng fenofibrat trong bán thành phẩm và viên nén","authors":"Phạm Lê Minh, Ngô Minh Thúy, Đào Thị Hương, Vũ Thị Thu Trang, Nguyễn Thị Kiều Anh","doi":"10.59882/1859-364x/152","DOIUrl":"https://doi.org/10.59882/1859-364x/152","url":null,"abstract":"Nghiên cứu đã xây dựng và thẩm định phương pháp sắc ký lớp mỏng hiệu năng cao (HPTLC) nhanh, đặc hiệu và chính xác để định lượng fenofibrat trong bán thành phẩm và viên nén. Pha tĩnh là bản mỏng nhôm tráng silicagel 60 F254, dung môi rửa giải gồm toluen - cloroform (4:7, tt/tt) cho vết chất phân tích gọn và rõ ràng (Rf là 0,50 ± 0,01). Chế độ đo độ hấp thụ ở bước sóng 298 nm bằng quét mật độ vết được sử dụng để định lượng. Phương pháp được thẩm định về độ chọn lọc, độ tuyến tính, độ đúng và độ chính xác theo hướng dẫn của ICH. Kết quả cho thấy, phương pháp có độ tuyến tính tốt (r = 0,999), độ chính xác trong ngày và độ chính xác khác ngày lần lượt là 0,73% và 0,98%, độ đúng nằm trong khoảng 98,1-100,3%. Phương pháp đã ứng dụng thành công trong định lượng chất phân tích trong cốm, bán thành phẩm và thành phẩm. Giá trị RSD của hàm lượng fenofibrate trong mẫu thử thấp (<1%) chứng tỏ phương pháp HPTLC xây dựng được phù hợp để áp dụng trong phân tích thường qui hoạt chất này trong kiểm tra chất lượng.","PeriodicalId":508364,"journal":{"name":"Tạp chí Nghiên cứu Dược và Thông tin Thuốc","volume":" 46","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139144877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Nguyen Thi Mai Phuong, Hua Thanh Thuy, Ong The Due, Phung Lam Toi, Do Thi Thu Hien, Nguyen Van Thanh, Vuong Trong Hieu, Pham Nu Hanh Van
Psoriatic arthritis (PsA) is a chronic, systemic inflammatory disease. This study assessed the cost-effectiveness of secukinumab, an interleukin-17A inhibitor, versus standard of care (SoC) from Vietnam’s National Health Insurance (NHI) perspective. Model-based cost-effectiveness analysis, the structure was a 3-month decision tree leading into a Markov model. Clinical parameters, including responses at 3 months, were from the FUTURE 2 trial. Cost parameters were from real data at the National Hospital of Dermatology and Venereology and a research period. The outcome included total costs and quality-adjusted life years (QALYs) over a life-time horizon (3.5% annual discount for both outcomes and cost), and incremental cost-effectiveness ratios (ICER). The robustness of the study findings was evaluated via sensitivity analysis. Patients treated with secukinumab achieved with QALY gain 1.16 versus SoC, but associated with higher total costs was 211.3 million VND over lifetime horizon. ICER for secukinumab vs SoC was 181.6 million VND lower than a willingness to pay threshold recommended in Vietnam (3GDP per capita equal to 286.8 million VND). Deterministic sensitivity analysis indicated that parameters related to Health Assessment Questionnaire scores were most influential. At the willingness to pay threshold of three times the GDPpc, the probability of secukinumab being cost-effective was 90.3% in the probabilistic sensitivity analysis. Secukinumab is a cost-effectiveness treatment versus SoC for PsA patients from the National health insurance’s perspective of Vietnam.
{"title":"Cost-effectiveness analysis of secukinumab versus standard of care in the treatment of psoriatic arthritis: A Vietnam National health insurance perspective","authors":"Nguyen Thi Mai Phuong, Hua Thanh Thuy, Ong The Due, Phung Lam Toi, Do Thi Thu Hien, Nguyen Van Thanh, Vuong Trong Hieu, Pham Nu Hanh Van","doi":"10.59882/1859-364x/122","DOIUrl":"https://doi.org/10.59882/1859-364x/122","url":null,"abstract":"Psoriatic arthritis (PsA) is a chronic, systemic inflammatory disease. This study assessed the cost-effectiveness of secukinumab, an interleukin-17A inhibitor, versus standard of care (SoC) from Vietnam’s National Health Insurance (NHI) perspective. Model-based cost-effectiveness analysis, the structure was a 3-month decision tree leading into a Markov model. Clinical parameters, including responses at 3 months, were from the FUTURE 2 trial. Cost parameters were from real data at the National Hospital of Dermatology and Venereology and a research period. The outcome included total costs and quality-adjusted life years (QALYs) over a life-time horizon (3.5% annual discount for both outcomes and cost), and incremental cost-effectiveness ratios (ICER). The robustness of the study findings was evaluated via sensitivity analysis. Patients treated with secukinumab achieved with QALY gain 1.16 versus SoC, but associated with higher total costs was 211.3 million VND over lifetime horizon. ICER for secukinumab vs SoC was 181.6 million VND lower than a willingness to pay threshold recommended in Vietnam (3GDP per capita equal to 286.8 million VND). Deterministic sensitivity analysis indicated that parameters related to Health Assessment Questionnaire scores were most influential. At the willingness to pay threshold of three times the GDPpc, the probability of secukinumab being cost-effective was 90.3% in the probabilistic sensitivity analysis. Secukinumab is a cost-effectiveness treatment versus SoC for PsA patients from the National health insurance’s perspective of Vietnam.","PeriodicalId":508364,"journal":{"name":"Tạp chí Nghiên cứu Dược và Thông tin Thuốc","volume":"24 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139228823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：